numares and the University of Oxford sign exclusive license agreement for new multi-marker diagnostics in multiple sclerosis
REGENSBURG, Germany, and OXFORD, England – (COMMERCIAL THREAD) –Leading company in NMR diagnostics Numares SA announced today that the company has signed an exclusive license agreement with Oxford University Innovation. this allows numbers translate and use the preliminary work of Oxford University on multiple sclerosis (MS) biomarkers for the development of a in vitro diagnostic test (IVD) capable of detecting disease progression earlier to improve patient management and outcomes. The exclusive license allows numbers further develop biomarkers into a diagnostic test based on multiple markers and their commercialization.
In about 85% of patients with MS, the disease initially follows a relapsing-remitting course. Most patients with “relapsing-remitting multiple sclerosis (RRMS)” will eventually switch to “secondary progressive multiple sclerosis (SPMS)” with continued worsening of symptoms. This transition is subtle and difficult to define clinically, requiring retrospective assessment of disease progression over the past 12 months. This delay in diagnosis prevents the rapid adoption of treatment regimens for effective patient management and better long-term clinical outcomes.
The collaboration between Oxford University and numbers began in 2017 with the common goal of validating a set of biomarkers, which had previously been identified by researchers at Oxford, to detect the transition from RRMS to SPMS. This used clinical data acquired from a multicenter cohort collected by the Oxford partners.
numbers provided his property AXINON® DIV system which provides standardized Magnetic group signaling (MGS®) measurements of metabolite levels in patient samples from nuclear magnetic resonance (NMR) spectroscopy. Based on these NMR data, the company is developing multi-marker algorithms for several diagnostic tests, combining relevant biomarkers into “biomarker constellations” and applying machine learning and other modeling approaches.
“We are excited to enter the next phase of the collaboration and use the excellent early scientific work from Oxford and figures’ expertise for the development of an MS IVD test based on the multi-marker approach ”, comments Volker Pfahlert, CEO of numbers. “Our mission is to improve patient care by providing better diagnostic tools to help physicians better manage their patients. This successful collaboration with Oxford researchers brings us closer to our shared goal of bringing first-class research to the bedside of MS patients.
Professor Daniel Anthony, head of the Experimental Neuropathology Laboratory in the Department of Pharmacology at the University of Oxford and lead scientist on the project, adds:
“We are very happy to have such industrial partner experienced in numbers to commercialize the results of our research as a revolutionary test, which allows for the first time the early detection of the transition from the RRMS stage to the SPMS stage. This will have a significant impact on the care of people living with MS. The test opens up the possibility of monitoring the condition more closely and thus improving treatment decision-making. ”
The development of IVD will begin in 2022. At the beginning of 2021, the two parties also agreed to extend their partnership for an additional two years and to extend the approach of the use of several markers in the diagnosis to the field of the disease. ‘Alzheimer’s.